Viatris was founded amid the COVID-19 pandemic and at a time of evolving healthcare needs.
A global pharmaceutical company, Viatris became operational in November 2020, following the merger or two major companies – Mylan and Upjohn – and they have an ambitious mission: to empower people to live healthier at every stage of life.
Although a newly formed company, they have long and strong roots in Ireland where they have had a presence for more than four decades. What’s more, Viatris has significant scale and are proud to be one of the largest pharmaceutical employers in the country, where nearly 2,000 highly skilled people work across six sites in Cork, Dublin (4) and Galway.
Viatris has a corporate office that is also a global and regional hub for many business functions as well as five manufacturing facilities. These sites are responsible for producing quality medicines from oral solid dosage forms such as tablets and capsules, sterile injectables that cover a wide range of therapeutic categories to complex branded and generic inhaled products. They also produce and supply active pharmaceutical ingredient, the central component of medicine.
At Viatris, they see healthcare not as it is, but as it should be. They act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Viatris empowers people worldwide to live healthier at every stage of life.
An industry leader with products that are capable of addressing nine of the top 10 causes of death
globally and serving more than 165 countries and territories including close to 90% of low and
Committed to providing a safe, positive, and productive work environment that fosters inclusion,
integrity, dignity and mutual respect.
Support efforts to enhance the quality of life and meet needs in and around the communities
where Viatris operates.
Responsible environmental stewardship and promoting safe and sustainable operations is a priority.
Leverage their global footprint to advocate for responsible public policy, prioritizing patient health,
access to medicine, including in low-income countries, and the acceptance of generics and biosimilars